Showing 321 - 340 results of 25,187 for search '(( 50 ((nn decrease) OR (((we decrease) OR (a decrease)))) ) OR ( 5 non decrease ))', query time: 0.64s Refine Results
  1. 321

    DataSheet1_Decreasing incidence and mortality of lung cancer in Hungary between 2011 and 2021 revealed by robust estimates reconciling multiple data sources.ZIP by Gabriella Gálffy (177759)

    Published 2024
    “…The COVID-19 pandemic resulted in a statistically significant decrease in lung cancer incidence, especially in the 50–59 age group (both sexes).…”
  2. 322
  3. 323

    DataSheet2_Decreasing incidence and mortality of lung cancer in Hungary between 2011 and 2021 revealed by robust estimates reconciling multiple data sources.xlsx by Gabriella Gálffy (177759)

    Published 2024
    “…The COVID-19 pandemic resulted in a statistically significant decrease in lung cancer incidence, especially in the 50–59 age group (both sexes).…”
  4. 324
  5. 325
  6. 326
  7. 327

    Differences among the classes of CAMs. by Daniel P. Bradley (10306893)

    Published 2025
    “…Some <i>N</i>-hydroxypyridinedione (HPD) HBV RNaseH inhibitors significantly reduced accumulation of capsids in HBV-replicating cells. A representative HPD <b>1466</b>, with a 50% effective concentration against HBV replication of 0.25 µM, decreased capsid and core protein accumulation by 50–90% in HepDES19 and HepG2.2.15 cells. …”
  8. 328
  9. 329
  10. 330
  11. 331

    S5 Fig - by Jian Zhong (329110)

    Published 2024
    “…Juglone inhibited LLC and A549 cells viability, with IC50 values of 10.78 μM and 9.47 μM, respectively, for 24 h, and substantially suppressed the migration and invasion of these two lung cancer cells. …”
  12. 332
  13. 333
  14. 334
  15. 335
  16. 336

    DataSheet1_Histamine H2 receptor antagonist exhibited comparable all-cause mortality-decreasing effect as β-blockers in critically ill patients with heart failure: a cohort study.Z... by Xue-Sha Zhang (17379385)

    Published 2023
    “…Furthermore, 30-day, 1-year, 5-year and 10-year all-mortality of patients in β-blockers + H2RAs group were significantly lower than those of patients in β-blockers group, respectively (HR: 0.64, 95%CI: 0.50–0.82 for 30-day; HR: 0.80, 95%CI: 0.69–0.93 for 1-year mortality; HR: 0.83, 95%CI: 0.74–0.93 for 5-year mortality; and HR: 0.85, 95%CI: 0.76–0.94 for 10-year mortality, respectively).…”
  17. 337
  18. 338
  19. 339
  20. 340